{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:44:56Z","timestamp":1791920696824,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.rpth.2026.106954","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:36:51Z","timestamp":1788968211000},"page":"106954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"10","author":[{"given":"Kristina","family":"Lindsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Nevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Colavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1577-2969","authenticated-orcid":false,"given":"Priya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Estevez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Khanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Uyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Pipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106954_bib1","series-title":"StatPearls [Internet]","author":"Killeen","year":"2026"},{"key":"10.1016\/j.rpth.2026.106954_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106954_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.15256\/joc.2011.1.2","article-title":"Haemophilia and joint disease: pathophysiology, evaluation, and management","volume":"1","author":"Knobe","year":"2011","journal-title":"J Comorb"},{"key":"10.1016\/j.rpth.2026.106954_bib4","series-title":"GeneReviews\u00ae","year":"1993"},{"key":"10.1016\/j.rpth.2026.106954_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221085202","article-title":"International consensus recommendations on the management of people with haemophilia B","volume":"13","author":"Hart","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106954_bib6","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106954_bib7","series-title":"HYMPAVZI\u00ae (marstacimab-hncq) injection, for subcutaneous use","year":"2026"},{"key":"10.1016\/j.rpth.2026.106954_bib8","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.2024027008","article-title":"Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study","volume":"145","author":"Young","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106954_bib9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106954_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2023-181263","article-title":"Efficacy and safety of the anti-tissue factor pathway inhibitor marstacimab in participants with severe hemophilia without inhibitors: results from the phase 3 basis trial","volume":"142","author":"Matino","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106954_bib11","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.jtha.2024.06.022","article-title":"Hemophilia prophylaxis: defining outcome measures by regulatory agencies and ISTH","volume":"22","author":"Visweshwar","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106954_bib12","author":"Higgins"},{"key":"10.1016\/j.rpth.2026.106954_bib13","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.rpth.2026.106954_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/hae.14689","article-title":"IDEAL study: a real-world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX-FP) in patients with haemophilia B in Italy","volume":"29","author":"Tagliaferri","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106954_bib15","doi-asserted-by":"crossref","unstructured":"Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 369:2313\u20132323.","DOI":"10.1056\/NEJMoa1305074"},{"key":"10.1016\/j.rpth.2026.106954_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.rpth.2026.106954_bib17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/jebm.12445","article-title":"The Freeman-Tukey double arcsine transformation for the meta-analysis of proportions: Recent criticisms were seriously misleading","volume":"14","author":"Doi","year":"2021","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.rpth.2026.106954_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.rpth.2026.106954_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12874-025-02527-z","article-title":"Overcoming challenges in prevalence meta-analysis: the case for the Freeman-Tukey transform","volume":"25","author":"Abdulmajeed","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.rpth.2026.106954_bib20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106954_bib21","series-title":"Presented at: ISTH 2023 Congress","article-title":"Results from BeneGene-1 study: prospective collection of bleeding rate in hemophilia B patients prior to phase 3 study (BeneGene-2) of fidanacogene elaparvovec","author":"Matino","year":"2023"},{"key":"10.1016\/j.rpth.2026.106954_bib23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2019-129439","article-title":"Is hemophilia B clinically less severe than hemophilia a? Evidence from the HUGS Va and Vb studies","volume":"134","author":"Ullman","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106954_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12916-021-02151-w","article-title":"Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study","volume":"19","author":"Nguyen","year":"2021","journal-title":"BMC Med"},{"key":"10.1016\/j.rpth.2026.106954_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/17474086.2024.2365929","article-title":"Outcome measures in hemophilia: current and future perspectives","volume":"17","author":"Benemei","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106954_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106954_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100047","article-title":"Risk factors for joint bleeding in severe hemophilia A and B: analysis of the Community Counts longitudinal surveillance cohort","volume":"2","author":"Manco-Johnson","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106954_bib28","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/cts.12794","article-title":"Annual bleeding rates: pitfalls of clinical trial outcomes in hemophilia patients","volume":"13","author":"Keipert","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.rpth.2026.106954_bib29","author":"Srivastava"},{"key":"10.1016\/j.rpth.2026.106954_bib30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/hae.70006","article-title":"Bleeding episodes in patients with haemophilia B receiving prophylactic factor IX treatment: a systematic review and meta-analysis","volume":"31","author":"Franchini","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106954_bib31","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/hae.14803","article-title":"Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: a systematic literature review","volume":"29","author":"Mannucci","year":"2023","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926036125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:47:45Z","timestamp":1791917265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926036125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2475037926036125"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106954","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding events in people with hemophilia B on prophylactic factor IX treatment: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106954","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106954"}}